Business Wire

Mitsui Chemicals and Prime Polymer Establish New PP Compounds Company in Netherlands

Jaa

Mitsui Chemicals, Inc. (TOKYO: 4183) (President & CEO: Tsutomu Tannowa) and Prime Polymer Co., Ltd. (President: Naoshi Hamada), owned 65 percent by Mitsui Chemicals and 35 percent by Idemitsu Kosan Co., Ltd. (TOKYO: 5019) (Representative Director & CEO: Shunichi Kito), announced today that the Group will establish Mitsui Prime Advanced Composites Europe B.V. in the Netherlands, together with Mitsui & Co., Ltd. (TOKYO: 8031) (President & CEO: Tatsuo Yasunaga). The new company will be Mitsui Chemicals’ first European production base for polypropylene (PP) compounds in response to growing global demand for automotive-use PP, it is scheduled to start operations in June 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180529005548/en/

Image of new factory in the Netherlands (Photo: Business Wire)

Image of new factory in the Netherlands (Photo: Business Wire)

Mitsui Chemicals Group currently operates eight production bases around the world (Japan, the U.S., Mexico, Europe, Thailand, China, India and Brazil) and has five research bases (Japan, the U.S., Europe, Thailand and China) and has continued to enhance its production systems, sales and R&D of high-performance PP compounds, which can be used to help reduce the weight of automobiles.

Recently strengthened environmental regulations have driven an increasing global need for lighter automobiles. As a result, demand for PP compounds is rising each year to meet light-weighting needs in bumpers, instrument panels and more. Mitsui Chemicals Group’s light-weight solutions are well accepted by automobile manufacturers all over the world and the Group expects to see its business expansion in Europe.

By establishing the new company with production, sales, technology service, and R&D function in the Netherlands, the Group reinforce close customer support providing effective light-weight solution in Europe and bolster the Group’s global network.

Mitsui Chemicals Group will continue to strengthen and expand PP compounds business through enhancing production, sales and technology service structure to supply high-quality products, responding to automobile manufacturers’ light-weight needs and their global development.

 

Overview of New Company

 

Company name (tentative)     Mitsui Prime Advanced Composites Europe B.V. (ACE)
Location   Chemelot Industrial Park, Limburg, the Netherlands
Establishment   June 2018
Capital   18.4 million euros
Ownership   Mitsui Chemicals, Inc.: 75%
Prime Polymer Co., Ltd.: 10%
    Mitsui & Co., Ltd.: 15%
Production capacity   30,000 tons/year
Beginning of operations     June 2020 (tentative)
 

About Mitsui Chemicals

Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industrial sector. Today, the company boasts many world-class products with over 150 companies in 30 countries. Its business portfolio includes environment-friendly materials for next-generation mobility, healthcare services to realize health and happiness in an ageing society, packaging that ensures the reliability and safety of food products, agrochemicals that contribute to increased production of food, electronic materials, and environment-friendly materials for the energy sector.

Contact information

Mitsui Chemicals Inc.
Yuri Matsunaga, +81-(3)-6253-2100
Corporate Communications Div.
yuuri.matsunaga@mitsuichemicals.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy21.5.2019 08:00:00 EESTTiedote

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005695/en/ Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels). The DIAMOND study is designed to further support the use of Veltassa® to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients. It is a global, multicentre, double-blind, placebo-controlled trial aiming to study approximately 2,400 patients in over 400 sites. Eligible patients wil

Concierge Auctions and Engel & Völkers to Sell $29.9 Million New Jersey Estate Without Reserve20.5.2019 20:32:00 EESTTiedote

A 32,507-square-foot Saddle River residence will sell at auction next month via leading global firm Concierge Auctions. Known as “Stone Palace on the Hill,” the home features a glass elevator, tennis court, racquetball court, wine cellar, and two swimming pools. 144 East Saddle River Road was previously listed for $29.9 million and will sell Without Reserve in cooperation with Alina Pogorelova and Lisa Troyano-Ascolese of Engel & Völkers. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on June 21st and close on June 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005686/en/ 144 East Saddle River Road | New York Metro, NJ (Photo: Business Wire) “The quality of work and detail that went into building this home is perhaps the most impressive element of the property,” said Troyano-Ascolese. “With astounding details from custom gold-plated and forged-iron railings to a complete hand-cut

CNIM to Optimize Renewable Heat Production for Nantes District Heating20.5.2019 20:20:00 EESTTiedote

CNIM, a French international industrial equipment manufacturer and integrator, has entered into an agreement concerning the energy efficiency optimisation at the waste-to-energy plant serving the cities of Nantes and Saint Nazaire, in the North West of France. Under the terms of this agreement, CNIM will install an absorption heat pump to boost the supply of hot water to Nantes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005678/en/ Heat-Pump_13MW_Brive (c) CNIM The delivery is scheduled for October 2019. The new system has been designed to inject 3.1 MW of heat energy into Nantes' district heating system. 2018: Two contracts to upgrade heat networks in France and Switzerland Prior to this agreement, CNIM won two other major contracts to upgrade the energy efficiency of waste-to-energy plants in France and Switzerland, and to supply district heating networks with renewable energy. Supplying 30 MW to Basel's district

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD120.5.2019 19:46:00 EESTTiedote

Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA. SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibro

MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä20.5.2019 18:55:00 EESTTiedote

MyHeritage, maailman johtava perhehistoria- ja DNA-testauspalvelu, ilmoitti tänään DNA-tuotevalikoimansa merkittävästä laajenemisesta MyHeritage Terveys+Perimä DNA-testin lanseeraamisen myötä. Testi tarjoaa uuden ulottuvuuden geneettiseen tietoon kattavien terveysraporttien avulla, mikä voi vaikuttaa terveys- ja elämäntapavalintoihin tulevaisuudessa. Se on nykyisen MyHeritage Vain-Perimä DNA-testin supersetti ja sisältää sen peruspilarit: etnisen alkuperän prosentuaalisen jakauman ja yhteisen, jaetun DNAn avulla löytyneet sukulaiset. MyHeritage on nyt ainoa maailmanlaajuinen DNA-yritys, joka tarjoaa kuluttajille kattavan terveys- ja perimä-tuotteen yli 40 kielellä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20190520005590/fi/ MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä (Graphic: Business Wire) Terveys+Perimä-tuotteen lanseeraus erottaa MyHerita

Airship Bolsters its Senior Leadership Team for Accelerated Global Growth20.5.2019 16:00:00 EESTTiedote

Customer engagement company Airship today announced four senior leadership appointments including Dale Flores as vice president of sales Americas, Neil Gariepy as vice president of infrastructure and security, David King Harris as vice president of sales EMEA, and Jeff Winsor as vice president of technology services. Dale Flores will lead the rapid expansion of Airship’s Americas sales organization, growing solution adoption to generate greater business value for customers throughout the region. Flores brings two decades of global SaaS sales and customer success management experience to Airship, including over 14 years leading sales teams at Silverpop and IBM. Most recently, Flores was head of customer success at digital customer experience company Clicktale. Neil Gariepy will lead Airship’s customer engineering, infrastructure and security teams, with responsibility for expanding Airship’s infrastructure globally while further optimizing its cost, performance and security. Gariepy bri

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme